Indication

As monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2362
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
09 August 2021
SMC meeting date:
06 July 2021
Patient group submission deadline:
03 May 2021